Sera Prognostics, (id:6837 SERA)
6.54 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 3:12:26 PM)
Exchange closed, opens in 18 hours 17 minutes
5.91 USD (5.91%)
5.48 USD (5.48%)
-12.92 USD (-12.92%)
-23.06 USD (-23.06%)
219.02 USD (219.02%)
-56.43 USD (-56.43%)
About Sera Prognostics,
Market Capitalization 220.87M
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
| Headquarters (address) |
2749 East Parleys Way Salt Lake City 84109 UT United States |
| Phone | 801 990 0520 |
| Website | https://seraprognostics.com |
| Employees | 55 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | SERA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.80 - 12.36 |
| Market Capitalization | 220.87M |
| P/E trailing | -5.56 |
| P/E forward | -12.34 |
| Price/Sale | 2,349.70 |
| Price/Book | 4.04 |
| Beta | 1.04 |
| EPS | -0.990 |
| EPS United States (ID:6, base:3402) | 24.22 |